The BRAF mutation affects a small percentage of non-small cell lung cancer (NSCLC) cases, making the cancer more difficult to treat. In recent years, advances in treatment have helped to improve ...

Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news. The recent approval by the ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...

Frequently affected by so-called oncogenic mutations, BRAF is implicated in several human cancers. In its normal state, the BRAF protein remains confined to an inactive form, through a mechanism of ...

The BRAF gene encodes a serine/threonine kinase that lies at a pivotal node of the mitogen-activated protein kinase (MAPK) signalling cascade. Activating mutations—most notably the V600E ...

SAN FRANCISCO -- First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the BREAKWATER ...

BRAF is the most commonly mutated gene associated with melanoma, found in more than 50 percent of patients. The gene encodes a cytoplasmic kinase that is a member of the MAPK signal-transduction ...

Merck, a leading global science and technology company, today announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now ...

Researchers have identified a range of genetic alterations in glioma brain cancers that will help them to understand how different mutations in one particular gene interact with other gene alterations ...

The BRAF mutation in lung cancer means that your cancer started due to a change in the BRAF gene. It may affect your treatment options and outlook. The BRAF gene is partially responsible for cell ...